Skip to content
drillr.ai

NSPR

InspireMD, Inc.

NASDAQ · ILHealthcareMedical - Devices
$0.70+0.33%

Price as of Jul 20, 2026

NSPR news

InspireMD, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    MIAMI, June 12, 2026 (GLOBE NEWSWIRE) --  InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD’s Board of Directors approved inducement grants to six (6) new non-executive employees in the aggregate amount of 91,161 shares of restricted stock (the “Inducement Grants”) outside of InspireMD’s 2021 Equity Incentive Plan, with a grant date as of Jun

    Globe Newswire ·

  2. InspireMD Reports First Quarter 2026 Financial Results

    - Reports total Q1 2026 revenue of $3.4 million, representing year-over-year growth of 122% - - Received IDE approval from FDA to initiate the CGUARDIANS III clinical trial of its SwitchGuard neuro protection system for use in TCAR procedures -             - FDA approval of the original CGuard delivery system anticipated in Q3 2026 - - On track for expected FDA approval of the CGuard Prime 80 cm for TCAR procedures in H2 2026, potentially doubling the Company’s addressable market - MIAMI, Ma

    Globe Newswire ·

  3. InspireMD Announces FDA Approval of Investigational Device Exemption Application for CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System

    MIAMI, May 01, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard(®) Prime carotid stent system for the prevention of stroke, today announced that the U.S. Food and Drug Administration (“FDA”) has approved the company’s Investigational Device Exemption (“IDE”) Application to initiate the CGUARDIANS III pivotal study of its SwitchGuard neuro protection system (“NPS”), including next generation enhancements from our prior IDE approval fo

    Globe Newswire ·

  4. InspireMD to Announce First Quarter 2026 Financial Results

    MIAMI, April 27, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard(®) Prime carotid stent system for the prevention of stroke, today announced that it will release its first quarter financial results on Monday, May 4, 2026. In conjunction with the release, InspireMD will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. Parties interested in participating by phone should register using this online

    Globe Newswire ·

  5. SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of InspireMD, Inc. (NASDAQ: NSPR)

    SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of InspireMD, Inc. (NASDAQ: NSPR) PR Newswire NEW YORK, April 14, 2026 NEW YORK, April 14, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating InspireMD, Inc. (NASDAQ: NSPR) on behalf of the company's shareholders. The investigation seeks to determine whether InspireMD's directors breached their fiduciary duties in connection with recent corporate actions. (https://mma.prnewswire.com/m

    PR Newswire ·

  6. InspireMD to Participate in Upcoming 25th Annual Needham Virtual Healthcare Conference

    MIAMI, March 31, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard(®) Prime carotid stent system for the prevention of stroke, today announced plans to present at the upcoming 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14(th) at 12:45 pm Eastern Time (ET). A live audio webcast and an archive of the recording will be available through the Investors page of InspireMD’s corporate website at https://investors.inspiremd.com. About InspireMD, Inc

    Globe Newswire ·